Back

Persevere Therapeutics treats first patient in Phase 2a ovarian cancer trial

Verifying
  • Persevere Therapeutics enrolled and treated the first patient in its MIROC-1 ovarian cancer trial.
  • The Phase 2a study will enroll 18 patients across four U.S. cancer centers.
  • The University of Pennsylvania treated the first patient; three additional sites are participating.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.